Zobrazeno 1 - 10
of 39
pro vyhledávání: '"COMBINATION CHEMOTHERAPY REGIMEN"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Christian G. Hartinger, Muhammad Hanif
Publikováno v:
Future Medicinal Chemistry. 10:615-617
Despite the severe side effects and the emergence of drug resistance, the use of DNA-targeting platinum drugs remains strong either alone or in a combination chemotherapy regimen. New strategies and formulations are being explored in the design of an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::194bf88a7be769214e3871fd6077845f
https://doi.org/10.4155/fmc-2017-0317
https://doi.org/10.4155/fmc-2017-0317
Autor:
Yoko Yashima, Naoki Sasahira, Yukiko Ito, Yousuke Nakai, Nobuo Toda, Minoru Tada, Keisuke Yamamoto, Toshihiko Arizumi, Kenji Hirano, Masao Omata, Hiroyuki Isayama, Osamu Togawa, Takashi Sasaki, Kazumichi Kawakubo, Hideaki Ijichi, Suguru Mizuno, Hirofumi Kogure, Takeshi Tsujino, Saburo Matsubara, Takao Kawabe, Hiroshi Yagioka
Publikováno v:
Oncology. 77:300-303
Objectives: We performed a pilot study of a modified combination chemotherapy regimen with S-1 plus gemcitabine for patients with advanced pancreatic cancer. Methods: Gemcitabine was administered at a dose of 1,000 mg/m2 in a 30-min intravenous injec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcbbbe28a25781e682bdf2de477f8c4d
https://doi.org/10.1159/000259616
https://doi.org/10.1159/000259616
Autor:
Simon Pacey, Paul M. Loadman, Gareth Griffiths, Alison Young, Margaret A. Knowles, Tracie-Ann Madden, Alison Birtle, Mirela Hategan, John D. Chester, Robert Jones, Sanjeev Kumar, Richard Adams, Angela C. Casbard, Javier Garcia Corbacho, Andrew Protheroe
Background: gemcitabine (G) and cisplatin (C) is a standard-of-care, combination chemotherapy regimen for neoadjuvant treatment of muscle-invasive and palliative treatment of advanced bladder cancer (BC). More effective regimens are urgently needed,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f38fcb7ea53c7acc828f1f3cbdfe7283
https://www.repository.cam.ac.uk/handle/1810/286033
https://www.repository.cam.ac.uk/handle/1810/286033
Autor:
Vincent C. Tam, Kelly Lien, Kelvin K. W. Chan, Yoo-Joung Ko, Matthew C. Cheung, Nicole Mittmann
Publikováno v:
Current Oncology
Volume 22
Issue 6
Pages 2592-452
Volume 22
Issue 6
Pages 2592-452
Previous Canadian cost-effectiveness analyses in cancer based on the EQ-5D-3L (EuroQoL, Rotterdam, Netherlands) have commonly used U.K. or U.S. tariffs because the Canadian equivalent only just recently became available. The implications of using non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::512382280696c155fe9b1aebdf95ab4c
Autor:
Andries H. Mulder, M. R. Schaafsma, Pieter Sonneveld, J.K. Doorduijn, L. F. Verdonck, M van Agthoven, Monique Steijaert, C.A. Uyl-de Groot, K. G. van der Hem, Gert J. Ossenkoppele, Gregor Verhoef, G. W. van Imhoff, B. van der Holt, M. H. J. Van Oers, M. H. H. Kramer, I. Buijt
Publikováno v:
Journal of Clinical Oncology, 21(16), 3041-3050. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 21(16), 3041-3050. American Society of Clinical Oncology
Journal of clinical oncology, 21(16), 3041-3050. American Society of Clinical Oncology
Journal of Clinical Oncology, 21(16), 3041-3050. American Society of Clinical Oncology
Journal of clinical oncology, 21(16), 3041-3050. American Society of Clinical Oncology
Purpose: To investigate whether the relative dose-intensity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy could be improved by prophylactic administration of granulocyte colony-stimulating factor (G-CSF) in elderly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76fb458dca7602bcb57de233e314bc01
https://doi.org/10.1200/jco.2003.01.076
https://doi.org/10.1200/jco.2003.01.076
Publikováno v:
Journal of Clinical Oncology. 35:e15747-e15747
e15747 Background: FOLFIRINOX is a highly effective combination chemotherapy regimen with the reputation of only being tolerable to young patients with good performance status. As the original ACCORD study was carried out at specific French universit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2fa4dbd12ede1e3f8cfc09deb8f9b24
https://doi.org/10.1200/jco.2017.35.15_suppl.e15747
https://doi.org/10.1200/jco.2017.35.15_suppl.e15747
Autor:
R. Lipp
Publikováno v:
Oncology Research and Treatment. 23:18-22
Introduction: Clinical studies performed in the USA and Europe within the past 3 years have shown that the combination chemotherapy regimen of CPT-11 (Campto®, irinotecan) plus 5-fluorouracil (5-FU) and folinic acid (FA) achieves a significantly bet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8df4d475e118b15df741e75176c5463
https://doi.org/10.1159/000055050
https://doi.org/10.1159/000055050
Publikováno v:
Scopus-Elsevier
The prognosis of aggressive non-Hodgkin's lymphoma (NHL) has improved greatly during recent years with the use of combination chemotherapy. Planning the treatment must take into consideration the patient's age, performance status, histological subtyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74bdfbfdae9234596c9bb13ff26ce1c9
https://doi.org/10.2165/00003495-199753060-00005
https://doi.org/10.2165/00003495-199753060-00005